Carrie Lofton
Acute Care · Las Vegas, NVNPI 1740560614
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $869 of the $1,273 with a category attached, or 68.2%. 10 manufacturers reported payments, led by Abbott at 56.0% of the total. Reporting peaked in 2024 at $768 and has fallen 72.6% since, to $211 in 2025.
Across 29 payments — averaging $43.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$713
- Novartis$116
- Alnylam Pharmaceuticals Inc.$112
- Philips North America LLC$107
- Lantheus Medical Imaging, Inc.$59
- Impulse Dynamics (USA) Inc.$57
- plus $109 from 4 others
What the payments were for
- Travel & lodging$40432%
- Food & beverage$86968%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $713 |
| Novartis | 7 | $116 |
| Alnylam Pharmaceuticals Inc. | 1 | $112 |
| Philips North America LLC | 4 | $107 |
| Lantheus Medical Imaging, Inc. | 3 | $59 |
| Impulse Dynamics (USA) Inc. | 1 | $57 |
| Merck | 2 | $50 |
| Boehringer Ingelheim | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$536
- ONPATTRO$112
How this compares
$1,273 in reported general payments places this provider in the 75th percentile of 129 acute care providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 469 | $615,611 |
| EntrestoSacubitril/Valsartan | 288 | $439,162 |
| VyndamaxTafamidis | 17 | $380,548 |
| JardianceEmpagliflozin | 185 | $280,751 |
| XareltoRivaroxaban | 97 | $135,429 |
| Repatha SureclickEvolocumab | 43 | $58,117 |
| FarxigaDapagliflozin Propanediol | 34 | $48,616 |
| Repatha SyringeEvolocumab | 14 | $16,882 |
| VascepaIcosapent Ethyl | 11 | $11,709 |
| Praluent PenAlirocumab | 12 | $10,226 |
| Metoprolol Succinate | 550 | $6,679 |
| Ranolazine ErRanolazine | 52 | $4,349 |
| Isosorbide Dinitrate | 63 | $3,771 |
| Atorvastatin Calcium | 509 | $3,625 |
| Spironolactone | 570 | $3,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $16 | $996,159486 claims |
| NovartisEntresto | $116 | $439,162288 claims |
| Boehringer IngelheimJardiance | $24 | $280,751185 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 129 acute care providers in Nevada.
Other acute care in Las Vegas
- Eileen JustoLas Vegas$20K
- Krystal CoffmanLas Vegas$6K
- Ticey HarrisLas Vegas$4K
- Bibi KooLas Vegas$4K
- Helen BallertLas Vegas$3K
- Chalisa PansinLas Vegas$3K
- Jenesa Aguiluz-DizonLas Vegas$2K
- Brianna AbneyLas Vegas$2K
- Anita LaksonLas Vegas$2K
- Christine ApelLas Vegas$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.